Inmed Pharmaceuticals Inc (INM) Stock Price, Quote & News

Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its pres...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 604 669 7207

Fax: 778 945 6800

Website: www.inmedpharma.com

Address:

885 West Georgia Street, Suite 1445, Vancouver, Canada

ItSaulGoodMaan Dec. 5 at 9:00 PM

$INM these patent news are always a five minute pump and dump

0 · Reply

ItSaulGoodMaan Dec. 5 at 8:59 PM

$INM wtf going on here

0 · Reply

Silver_Bullet26 Dec. 5 at 8:58 PM

$INM & $SPY Big news!!

0 · Reply

AlertsAndNews Dec. 5 at 8:57 PM

$INM patent headline into the close here

0 · Reply

PatentGrants Dec. 5 at 8:56 PM

$INM InMed Pharmaceuticals has received a Notice of Allowance for a US patent titled "CANNABINOID ANALOGS AND METHODS FOR THEIR PREPARATION (USEFUL FOR NEUROLOGICAL CONDITIONS, MOOD/BEHAVIOR DISORDERS, INFECTIONS, AND CANCERS)". https://patentcenter.uspto.gov/applications/17289868/ifw/docs

0 · Reply

Silver_Bullet26 Dec. 5 at 8:35 PM

$INM & $TGL Both having a Great day!

0 · Reply

aw20 Dec. 5 at 8:34 PM

$INM road to +2 👀

0 · Reply

ViperV22 Dec. 5 at 8:34 PM

$INM

0 · Reply

Silver_Bullet26 Dec. 5 at 8:25 PM

$INM Looking good here. Slow steady climb

0 · Reply

aw20 Dec. 5 at 7:33 PM

$INM breaking out 👀

0 · Reply

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Nov 6, 2025, 4:51 PM EST - 4 weeks ago

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Oct 16, 2025, 8:30 AM EDT - 7 weeks ago

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Oct 9, 2025, 8:30 AM EDT - 2 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

ZYME

Sep 23, 2025, 8:30 AM EDT - 2 months ago

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 16, 2025, 1:39 PM EDT - 2 months ago

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Sep 5, 2025, 1:33 PM EDT - 3 months ago

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Jul 28, 2025, 7:00 AM EDT - 4 months ago

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Jun 27, 2025, 7:00 AM EDT - 5 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 25, 2025, 8:00 AM EDT - 5 months ago

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 24, 2025, 7:00 AM EDT - 5 months ago

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 13, 2025, 4:30 PM EDT - 6 months ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

May 12, 2025, 6:00 PM EDT - 7 months ago

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 6:54 PM EST - 10 months ago

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 3, 2025, 7:30 AM EST - 10 months ago

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Jan 22, 2025, 7:30 AM EST - 11 months ago

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 21, 2025, 7:30 AM EST - 11 months ago

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Dec 18, 2024, 8:00 PM EST - 1 year ago

InMed Announces Results of 2024 Annual General Meeting

Dec 17, 2024, 4:56 PM EST - 1 year ago

InMed Enters Into Standby Equity Purchase Agreement

Nov 19, 2024, 7:30 AM EST - 1 year ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 14, 2024, 4:45 PM EST - 1 year ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 8, 2024, 4:44 PM EST - 1 year ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 5, 2024, 8:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Oct 28, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 1 year ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 22, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Sep 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 20, 2024, 4:30 PM EDT - 1 year ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Aug 21, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 20, 2024, 10:10 AM EDT - 1 year ago

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Aug 20, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Jul 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jun 10, 2024, 5:18 PM EDT - 1 year ago

InMed to Present at the Emerging Growth Conference

May 14, 2024, 8:30 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Apr 18, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 16, 2024, 8:00 AM EDT - 1 year ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 4, 2024, 8:00 AM EDT - 1 year ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Mar 20, 2024, 8:30 AM EDT - 1 year ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Feb 13, 2024, 5:41 PM EST - 1 year ago

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Feb 9, 2024, 8:00 AM EST - 1 year ago

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Jan 18, 2024, 4:41 PM EST - 2 years ago

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Jan 16, 2024, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Dec 19, 2023, 6:03 PM EST - 2 years ago

InMed Announces Results of 2023 Annual General Meeting

Nov 14, 2023, 8:04 AM EST - 2 years ago

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

Nov 2, 2023, 8:00 AM EDT - 2 years ago

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

Oct 26, 2023, 7:15 PM EDT - 2 years ago

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

Oct 24, 2023, 4:38 PM EDT - 2 years ago

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

Oct 24, 2023, 7:30 AM EDT - 2 years ago

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

Sep 29, 2023, 1:21 PM EDT - 2 years ago

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

Sep 22, 2023, 6:15 PM EDT - 2 years ago

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

ItSaulGoodMaan Dec. 5 at 9:00 PM

$INM these patent news are always a five minute pump and dump

0 · Reply

ItSaulGoodMaan Dec. 5 at 8:59 PM

$INM wtf going on here

0 · Reply

Silver_Bullet26 Dec. 5 at 8:58 PM

$INM & $SPY Big news!!

0 · Reply

AlertsAndNews Dec. 5 at 8:57 PM

$INM patent headline into the close here

0 · Reply

PatentGrants Dec. 5 at 8:56 PM

0 · Reply

Silver_Bullet26 Dec. 5 at 8:35 PM

$INM & $TGL Both having a Great day!

0 · Reply

aw20 Dec. 5 at 8:34 PM

$INM road to +2 👀

0 · Reply

ViperV22 Dec. 5 at 8:34 PM

$INM

0 · Reply

Silver_Bullet26 Dec. 5 at 8:25 PM

$INM Looking good here. Slow steady climb

0 · Reply

aw20 Dec. 5 at 7:33 PM

$INM breaking out 👀

0 · Reply

Space0 Dec. 5 at 7:31 PM

$INM is showing good movement

0 · Reply

aw20 Nov. 28 at 6:00 PM

$INM

0 · Reply

rangervs Nov. 28 at 5:29 PM

$INM $2+ would be a start!

0 · Reply

ppl_first Nov. 28 at 2:43 PM

$INM any chance of an upcoming turnaround for this dog? I’m stuck

1 · Reply

issi62 Nov. 26 at 6:10 PM

$INM lesson learn't, ain't no one really going to help you print money. There is always a catch. Always do your own DD.

0 · Reply

DukeMCG Nov. 26 at 11:10 AM

$INM Geeze, looks like DBR suckered me into this one too...I should have known...LOL

1 · Reply

321rip Nov. 26 at 10:50 AM

$INM 248 am pst, INM no trades, $INHD +26% & counting

0 · Reply

targatrader Nov. 26 at 1:57 AM

$INM would seriously stay away from this one. They really have zero going for them. No revenue. I mean I guess if you believe one day cannabinoids will cure something, but it’s been years and years. Stay away as an investor and if you are trying to trade it…sell before the Dr dumps on you.

2 · Reply

TradeHuntFish Nov. 25 at 11:23 PM

$AEHL $CETY $INM $KZIA $PAVS All eyes on DGLY🚨 news , bottomed, tiny float, almost 0 borrow , nearly $10 intrinsic value…

0 · Reply

ppl_first Nov. 25 at 9:59 PM

$INM Breaking down a little after hours, hate to see what happens tomorrow morning.

0 · Reply

Junkiejingle Nov. 25 at 8:58 PM

$INM All ight Mr island… I’m in

0 · Reply

aw20 Nov. 25 at 8:51 PM

$INM +2 in After hours? 👀

0 · Reply

Market Cap	3.76M
Revenue (ttm)	4.94M
Net Income (ttm)	-8.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-165.18%
Debt to Equity Ratio	0.00

Volume	419,600
Avg Vol	409,816
Day's Range	N/A - N/A
Shares Out	2.80M
Stochastic %K	75%
Beta	0.31
Analysts	Strong Buy
Price Target	$45.00